Scientists Identify Receptor for Papillomavirus

OncologyONCOLOGY Vol 11 No 5
Volume 11
Issue 5

Researchers at the University of Queensland, Australia, have identified the receptor on human skin and mucosal cells that they believe allows papillomaviruses to attach to and infect those cells.

Researchers at the University of Queensland, Australia, have identifiedthe receptor on human skin and mucosal cells that they believe allows papillomavirusesto attach to and infect those cells.

Human papillomaviruses are responsible for a variety of warts in humans,including skin, foot, laryngopharyngeal, and some types of genital warts.They are also considered to be a major risk factor for the developmentof certain types of cancer.

In the study, reported in the March issue of the Journal of Virology,researchers investigated the interaction of papillomavirus-like particles(VLPs) with two epithelial cell lines. Using a number of different assays,they found that alpha-6-integrin can interact with VLPs, suggesting thatit may function as a cellular receptor for papillomaviruses.

Papillomavirus infects only skin and mucosal surfaces, and this restrictionis thought to be mediated by interactions of the virus with host cell factors.In general, the first step in infection with a crystalline virus is attachmentof the virus to a specific receptor on the surface of the susceptible hostcell. Until now, the receptor for papillomavirus had yet to be found.

"Identification of a receptor for PV [papillomavirus] particlesshould lead to identification of residues on the PV particle that are criticalfor PV binding and uptake and may allow a rational approach to design ofdrugs to inhibit the process of PV infection," say the researchers.

Related Videos
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
Cervical Cancer
woman speaking with physician
Related Content